MOSES RODRIGUEZ, M.D.
Neurology at 1 St, Rochester, MN
License number
Minnesota 24112
Category
Neurology
Type
Neurology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about MOSES RODRIGUEZ at bizstanding.comMoses Rodriguez MD
200 1 St SW, Rochester, MN 55905
Industry:
Neurologist
Site:
Phone:
(507) 284-1588 (Phone)
Moses Rodriguez
Mayo Clinic - Moses Rodriguez MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Physicians & Surgeons
Phone:
(507) 284-2511 (Phone)
Professional information
Compositions And Methods Including A Recombinant Human Mab That Promotes Cns Remyelination
US Patent:
8460665, Jun 11, 2013
Filed:
May 17, 2004
Appl. No.:
10/557115
Inventors:
Elliot A. Gruskin - Malvern PA, US
Eric Chojnicki - Houston TX, US
Arthur E. Warrington - Rochester MN, US
Allan J. Bieber - Rochester MN, US
Moses Rodriguez - Rochester MN, US
Eric Chojnicki - Houston TX, US
Arthur E. Warrington - Rochester MN, US
Allan J. Bieber - Rochester MN, US
Moses Rodriguez - Rochester MN, US
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
Acorda Therapeutics, Inc. - Ardsley NY
Acorda Therapeutics, Inc. - Ardsley NY
International Classification:
A61K 39/395
US Classification:
4241411, 4241351, 4241721
Abstract:
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.
Treatment Of Central Nervous System Diseases By Antibodies Against Glatiramer Acetate
US Patent:
6800285, Oct 5, 2004
Filed:
Jun 20, 2001
Appl. No.:
09/885227
Inventors:
Moses Rodriguez - Rochester MN 55902
Daren Ure - Rochester MN 55901
Daren Ure - Rochester MN 55901
International Classification:
A61K 39395
US Classification:
4241331, 4241301, 4241411, 4241391, 5303871, 5303873, 5303879, 5303881
Abstract:
The present invention provides humanized polyclonal and humanized monoclonal antibodies directed against an epitope on glatiramer acetate, also known as Copolymer 1, Copolymer-1, Cop-1 or Cop. Additionally, the subject invention concerns a pharmaceutical composition comprising an antibody directed against an epitope on glatiramer acetate for the treatment of a disease associated with demyelination of central nervous system axons. Also encompassed by the subject invention is a method of treating a subject suffering from a disease associated with demyelination of central nervous system axons. The subject invention further contains methods of stimulating remyelination of central nervous system axons. In addition, the subject invention provides a method of stimulating proliferation of lymphocytes.
Human Igm Antibodies, And Diagnostic And Therapeutic Uses Thereof Particularly In The Central Nervous System
US Patent:
2011010, May 5, 2011
Filed:
Jul 29, 2010
Appl. No.:
12/845936
Inventors:
Moses Rodriguez - Rochester MN, US
David J. Miller - Ridgeway WI, US
Larry R. Pease - Rochester MN, US
David J. Miller - Ridgeway WI, US
Larry R. Pease - Rochester MN, US
International Classification:
A61K 51/10, C07K 16/28, A61K 49/00, G01N 33/566
US Classification:
424 149, 5303891, 424 91, 435 721
Abstract:
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.
Treatment Of Central Nervous System Diseases By Antibodies Against Glatiramer Acetate
US Patent:
2005001, Jan 27, 2005
Filed:
Feb 10, 2004
Appl. No.:
10/776442
Inventors:
Moses Rodriguez - Rochester MN, US
Daren Ure - Rochester MN, US
Daren Ure - Rochester MN, US
International Classification:
A61K039/395
US Classification:
424131100, 530387200
Abstract:
The present invention provides humanized polyclonal and humanized monoclonal antibodies directed against an epitope on glatiramer acetate, also known as Copolymer 1, Copolymer-1, Cop-or Cop. Additionally, the subject invention concerns a pharmaceutical composition comprising an antibody directed against an epitope on glatiramer acetate for the treatment of a disease associated with demyelination of central nervous system axons. Also encompassed by the subject invention is a method of treating a subject suffering from a disease associated with demyelination of central nervous system axons. The subject invention further contains methods of stimulating remyelination of central nervous system axons. In addition, the subject invention provides a method of stimulating proliferation of lymphocytes.
Monoclonal Antibodies Which Promote Central Nervous System Remyelination
US Patent:
5591629, Jan 7, 1997
Filed:
Apr 29, 1994
Appl. No.:
8/236520
Inventors:
Moses Rodriguez - Rochester MN
David J. Miller - Rochester MN
David J. Miller - Rochester MN
Assignee:
Mayo Foundation for Medical Education & Research - Rochester MN
International Classification:
C07K 1628, C12N 512
US Classification:
43524027
Abstract:
Monoclonal IgM antibodies which promote central nervous system remyelination when given to a mammal afflicted with a demyelinating disease are disclosed. These antibodies show multi-organ autoreactivity, and recognize both surface and cytoplasmic determinants on glial cells.
Promotion Of Central Nervous System Remyelination Using Monoclonal Autoantibodies
US Patent:
2002016, Nov 7, 2002
Filed:
Jan 7, 1997
Appl. No.:
08/779784
Inventors:
MOSES RODRIGUEZ - ROCHESTER MN, US
DAVID J. MILLER - FALLSTON MD, US
KUNIHIKO ASAKURA - ROCHESTER MN, US
DAVID J. MILLER - FALLSTON MD, US
KUNIHIKO ASAKURA - ROCHESTER MN, US
International Classification:
A61K039/395
US Classification:
424/130100
Abstract:
Methods are described for treating demyelinating diseases in mammals, such as multiple sclerosis in humans, and viral diseases of the central nervous system of humans and domestic animals, such as post-infectious encephalomyelitis, or prophylactly inhibiting the initiation or progression of demyelination in these disease states, using the monoclonal autoantibodies SCH 94.03, SCH 79.08, O1, O4, A2B5, HNK-1, active fragments thereof and natural or synthetic autoantibodies having the characteristics of mAb SCH 94.03, SCH 79.08, O1, O4, A2B5 and HNK-1.
Human Monoclonal Antibodies Against Amyloid Beta Protein, And Their Use As Therapeutic Agents
US Patent:
2011002, Feb 3, 2011
Filed:
Mar 24, 2009
Appl. No.:
12/934773
Inventors:
Moses Rodriguez - Rochester MN, US
Larry R. Pease - Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Nilufer Taner - Jacksonville FL, US
Larry R. Pease - Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Nilufer Taner - Jacksonville FL, US
International Classification:
A61K 39/395, A61P 25/28
US Classification:
4241421
Abstract:
Materials and methods for identifying human natural anti-Aβ autoantibodies, as well as materials and methods for using such antibodies to treat Alzheimer's disease.
Method Of Treating Autoimmune And/Or Viral-Induced Diseases That Are Mediated By Cd8 Phenotype T Cells
US Patent:
5660828, Aug 26, 1997
Filed:
Jan 6, 1994
Appl. No.:
8/177806
Inventors:
Moses Rodriguez - Rochester MN
Subramaniam Sriram - Burlington VT
Subramaniam Sriram - Burlington VT
Assignee:
Mayo Foundation for Medical Education & Research - Rochester MN
University of Vermont and State Agricultural College - Burlington VT
University of Vermont and State Agricultural College - Burlington VT
International Classification:
A61K 39395, A61K 4505, C07K 100, C07K 1400
US Classification:
4241541
Abstract:
A method to block cytolytic activity of CD8 phenotype T cells using an effective amount of a complement-fixing anti CD8 antibody is described. The anti CD8 antibody may be used to treat patients with immunopathologic disorders induced by viruses or (autoimmune diseases) such as multiple sclerosis, viral or post-viral polyneuropathy, viral or post-viral myocarditis, insulitis, encephalomyelitis, myositis, synovitus, and arthritis.
Dendritic Cell Potentiation
US Patent:
2011006, Mar 17, 2011
Filed:
Jun 30, 2010
Appl. No.:
12/827283
Inventors:
Larry R. Pease - Rochester MN, US
Moses Rodriguez - Rochester MN, US
Daren R. Ure - Edmonton, CA
Bogoljub Ciric - Philadelphia PA, US
Virginia Van Keulen - Rochester MN, US
Moses Rodriguez - Rochester MN, US
Daren R. Ure - Edmonton, CA
Bogoljub Ciric - Philadelphia PA, US
Virginia Van Keulen - Rochester MN, US
Assignee:
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH - Rochester MN
International Classification:
C12N 5/10, C07H 21/00, C12N 15/63
US Classification:
435325, 536 231, 536 2353, 4353201
Abstract:
A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.
Methods And Materials For Treating Inflammatory Conditions
US Patent:
2011000, Jan 13, 2011
Filed:
Jul 9, 2010
Appl. No.:
12/833773
Inventors:
Isobel A. Scarisbrick - Rochester MN, US
Sachiko I. Blaber - Tallahassee FL, US
Michael Blaber - Tallahassee FL, US
Moses Rodriguez - Rochester MN, US
Sachiko I. Blaber - Tallahassee FL, US
Michael Blaber - Tallahassee FL, US
Moses Rodriguez - Rochester MN, US
International Classification:
C12Q 1/68, C07H 21/04, G01N 33/573, G01N 33/566
US Classification:
435 6, 536 245, 435 74, 436501
Abstract:
Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity.